Cleared Traditional

K933078 - BECKMAN ALPHA-1-MICROGLOBULIN (A1M) REAGENT (FDA 510(k) Clearance)

Class I Immunology device.

K933078 · Beckman Instruments, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1994
Decision
202d
Days
Class 1
Risk

K933078 is an FDA 510(k) clearance for the BECKMAN ALPHA-1-MICROGLOBULIN (A1M) REAGENT. Classified as Alpha-1 Microglobulin, Antigen, Antiserum, Control (product code MGA), Class I - General Controls.

Submitted by Beckman Instruments, Inc. (Brea, US). The FDA issued a Cleared decision on January 11, 1994 after a review of 202 days - an extended review cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5400 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Beckman Instruments, Inc. devices

Submission Details

510(k) Number K933078 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 23, 1993
Decision Date January 11, 1994
Days to Decision 202 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
98d slower than avg
Panel avg: 104d · This submission: 202d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code MGA Alpha-1 Microglobulin, Antigen, Antiserum, Control
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.5400
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.